Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer
癌症中新型致癌 ALK 变体转录激活的表观遗传机制
基本信息
- 批准号:10394271
- 负责人:
- 金额:$ 48.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAdenocarcinoma CellAlgorithmsAllelesAutomobile DrivingBRAF geneBindingBioinformaticsBiological ModelsCRISPR interferenceCRISPR/Cas technologyCell LineChIP-seqChromatinChromatin Conformation Capture and SequencingChromatin Remodeling FactorClear cell renal cell carcinomaClinicalClustered Regularly Interspaced Short Palindromic RepeatsCombination immunotherapyComplexCutaneous MelanomaDNADataDevelopmentDistalElementsEngineeringEnhancersEpigenetic ProcessExtracellular DomainGene ExpressionGenomicsIn VitroIntronsInvestigationKidneyLightLungLung AdenocarcinomaMAP Kinase GeneMAPK1 geneMEKsMalignant NeoplasmsMediatingMelanoma CellMethodologyModernizationMutateMutationNatureNivolumabNormal tissue morphologyOncogene ActivationOncogenesOncogenicOther GeneticsPathogenesisPatientsPhosphotransferasesPlayProteinsQuality of lifeRNA InterferenceRefractoryRegulationRegulatory ElementRenal Cell CarcinomaResistanceRoleSamplingShapesSignal PathwaySignal TransductionSmall Interfering RNASomatic MutationSquamous cell carcinomaSystemSystemic TherapyTechnologyThe Cancer Genome AtlasTherapeuticTranscriptTranscription InitiationTranscription Initiation SiteTranscriptional ActivationTranscriptional RegulationTransmembrane DomainUveal MelanomaVariantXenograft procedurecancer typecell immortalizationcell transformationchromosome conformation captureclinical investigationclinically relevantcrizotinibgenome-widehistone modificationin vivoinhibitorinsightipilimumabknock-downmalignant stomach neoplasmmelanomamultidisciplinarymutantnovelnovel therapeutic interventionpromoterrecruitstandard of caresuccesstargeted treatmenttranscription factortranscriptome sequencingtreatment responsetumortumorigenesis
项目摘要
Abstract
Comprehensive genomic characterization in cancer has revolutionized our understanding of cancer
pathogenesis and provided the scientific rationale for the clinical success of targeted therapies in a variety of
cancers. There is emerging evidence that oncogenes activated through epigenetic mechanisms are also
important in oncogenic transformation and can dictate therapeutic responses. We recently discovered a novel
oncogenic ALK variant, ALKATI, arising through alternative transcription initiation independent of genetic
alteration, in 3.4% of all TCGA cancers, including 12% of melanomas and less frequently in other cancer types.
The ALKATI can stimulate multiple signaling pathways and is capable of driving oncogenic transformation in
immortalized cells in vitro and drive tumorigenesis in vivo. Moreover, engineered ALKATI-transformed cells and
tumors, and ALKATI-positive patient derived cell lines and xenografts are sensitive to ALK inhibitors. A patient
with ALKATI-positive advanced melanoma who has progressed on standard of care systemic therapy and
investigational combination immunotherapy of nivolumab and ipilimumab derived significant clinical benefit
from Crizotinib (an ALK inhibitor) with tumor shrinkage and improvement in quality of life. These data have
provided the scientific rationale and enthusiasm for the current clinical investigations of ALK-targeted therapies
in therapeutic refractory advanced melanoma.
ALKATI is not expressed in normal tissues. It is biallelically expressed in tumor samples. These observations,
together with the lack of somatic mutations at the ALK locus in the ALKATI-positive tumor samples, indicate that
the ALKATI transcriptional activation is through epigenetic mechanisms. Our preliminary data further indicate
that MAPK signaling regulates ALKATI expression. Here, we proposes systematic and comprehensive
investigations focused on understanding the epigenetic mechanisms in the following three aims: 1) Define the
three-dimensional chromatin organization of the long-range interacting elements with the ALKATI transcriptional
start site (the ALK-ATI site); 2) Identify and characterize the chromatin modifier(s) involved in ALKATI
transcriptional regulation; 3) Elucidate the regulatory mechanisms of ALKATI expression by MAPK signaling in
melanoma. We will use modern technologies, including RNA-seq, ChIP-seq, 4C-seq, CRISPR, CRISPR
interference (CRISPRi) systems, bioinformatics and integrative analyses, and a repertoire of well-characterized
ALKATI-positive and ALKATI-negative cell lines for the proposed multidisciplinary studies. We anticipate that
these mechanistic studies will provide insight on not only the basic epigenetic mechanisms in oncogene
transcriptional activation through alternative transcription initiation in cancer, but also novel epigenetic
therapeutic strategies to target the oncogene transcriptional activation through similar mechanisms.
摘要
癌症的全面基因组表征彻底改变了我们对癌症的理解
发病机制,并为靶向治疗在各种疾病中的临床成功提供了科学依据。
癌的有新的证据表明,通过表观遗传机制激活的癌基因也是
在致癌转化中很重要,并且可以决定治疗反应。我们最近发现了一本小说
致癌ALK变体ALKATI,通过不依赖于遗传的交替转录起始产生
在所有TCGA癌症的3.4%中,包括12%的黑色素瘤,在其他癌症类型中频率较低。
ALKATI可以刺激多种信号传导途径,并能够驱动肿瘤细胞的致癌转化。
在体外使细胞永生化并在体内驱动肿瘤发生。此外,工程改造的ALKATI转化细胞和
肿瘤和ALKATI阳性患者来源的细胞系和异种移植物对ALK抑制剂敏感。患者
患有ALKATI阳性晚期黑色素瘤,在标准治疗全身治疗中进展,
纳武单抗和伊匹单抗研究性联合免疫疗法获得显著的临床益处
克唑替尼(一种ALK抑制剂)治疗,肿瘤缩小,生活质量改善。这些数据
为当前ALK靶向治疗的临床研究提供了科学依据和热情
治疗难治性晚期黑色素瘤
ALKATI在正常组织中不表达。它在肿瘤样品中双等位基因表达。这些观察,
以及ALKATI阳性肿瘤样本中ALK基因座缺乏体细胞突变,表明
ALKATI转录激活是通过表观遗传机制进行的。我们的初步数据进一步表明
MAPK信号调节ALKATI表达。在此,我们提出系统全面的
研究集中在以下三个目标的理解表观遗传机制:1)定义
与ALKATI转录因子的长程相互作用元件的三维染色质组织
起始位点(ALK-ATI位点); 2)识别和表征参与ALKATI的染色质修饰剂
转录调控; 3)阐明ALKATI表达通过MAPK信号转导的调节机制,
黑素瘤我们将使用现代技术,包括RNA-seq,ChIP-seq,4C-seq,CRISPR,CRISPR
干扰(CRISPRi)系统,生物信息学和综合分析,以及一个良好表征的
用于拟定多学科研究的ALKATI阳性和ALKATI阴性细胞系。我们预计
这些机制的研究不仅将提供对癌基因的基本表观遗传机制的了解,
癌症中通过交替转录起始的转录激活,以及新的表观遗传
通过类似机制靶向癌基因转录激活的治疗策略。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Charles David Allis (1951-2023).
查尔斯·大卫·艾利斯(1951-2023)。
- DOI:10.1038/s41588-023-01331-z
- 发表时间:2023
- 期刊:
- 影响因子:30.8
- 作者:Chi,Ping;Lewis,PeterW;Lu,Chao;Lu,Janice;Ruthenburg,AlexanderJ;Sabari,BenjaminR;Shechter,David;Wan,Liling;Wang,GangGreg
- 通讯作者:Wang,GangGreg
Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling.
- DOI:10.1074/jbc.ra120.015352
- 发表时间:2021-01
- 期刊:
- 影响因子:0
- 作者:Ceraudo E;Horioka M;Mattheisen JM;Hitchman TD;Moore AR;Kazmi MA;Chi P;Chen Y;Sakmar TP;Huber T
- 通讯作者:Huber T
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.
- DOI:10.1038/s41467-022-30496-0
- 发表时间:2022-06-15
- 期刊:
- 影响因子:16.6
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ping Chi其他文献
Ping Chi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ping Chi', 18)}}的其他基金
Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancer
利用双链 RNA (dsRNA) 反应和 PRC2 失活癌症的抗肿瘤作用
- 批准号:
10638759 - 财政年份:2023
- 资助金额:
$ 48.87万 - 项目类别:
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
ASTX727 在 PRC2 缺失恶性周围神经鞘瘤 (MPNST) 患者中的 II 期研究
- 批准号:
10502752 - 财政年份:2022
- 资助金额:
$ 48.87万 - 项目类别:
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
ASTX727 在 PRC2 缺失恶性周围神经鞘瘤 (MPNST) 患者中的 II 期研究
- 批准号:
10707164 - 财政年份:2022
- 资助金额:
$ 48.87万 - 项目类别:
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)
了解和靶向 NF1 缺陷的恶性周围神经鞘瘤 (MPNST) 中的 MAPK 通路激活
- 批准号:
10376770 - 财政年份:2021
- 资助金额:
$ 48.87万 - 项目类别:
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)
了解和靶向 NF1 缺陷的恶性周围神经鞘瘤 (MPNST) 中的 MAPK 通路激活
- 批准号:
10657337 - 财政年份:2021
- 资助金额:
$ 48.87万 - 项目类别:
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)
了解和靶向 NF1 缺陷的恶性周围神经鞘瘤 (MPNST) 中的 MAPK 通路激活
- 批准号:
10156866 - 财政年份:2021
- 资助金额:
$ 48.87万 - 项目类别:
Clinical Scholars Biomedical Research Training Program
临床学者生物医学研究培训计划
- 批准号:
10179325 - 财政年份:2019
- 资助金额:
$ 48.87万 - 项目类别:
Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer
癌症中新型致癌 ALK 变体转录激活的表观遗传机制
- 批准号:
10113559 - 财政年份:2018
- 资助金额:
$ 48.87万 - 项目类别:
Phase2 trial of MEK162 & imatinib combined therapy in GIST, IND119794(09/20/2013)
MEK162的2期试验
- 批准号:
9567835 - 财政年份:2017
- 资助金额:
$ 48.87万 - 项目类别:
Phase2 trial of MEK162 & imatinib combined therapy in GIST, IND119794(09/20/2013)
MEK162的2期试验
- 批准号:
9762575 - 财政年份:2017
- 资助金额:
$ 48.87万 - 项目类别:
相似海外基金
Assessing The Impact of Heparanase and NDST2 Expression on Non-Small Cell Lung Adenocarcinoma Cell Motility
评估乙酰肝素酶和 NDST2 表达对非小细胞肺腺癌细胞运动的影响
- 批准号:
449570 - 财政年份:2020
- 资助金额:
$ 48.87万 - 项目类别:
Studentship Programs
Analysis of cancer metastasis and invasion mechanism using a new lung adenocarcinoma cell line.
使用新的肺腺癌细胞系分析癌症转移和侵袭机制。
- 批准号:
16K10689 - 财政年份:2016
- 资助金额:
$ 48.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Acquisition strategy of tumor-specific markers using established micropapillary pattern pulmonary adenocarcinoma cell line
使用已建立的微乳头模式肺腺癌细胞系获取肿瘤特异性标志物的策略
- 批准号:
26460441 - 财政年份:2014
- 资助金额:
$ 48.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The antibetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
抗生素药物二甲双胍在体外和体内抑制食管腺癌细胞增殖。
- 批准号:
25860540 - 财政年份:2013
- 资助金额:
$ 48.87万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
The cell permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferations and can be used as the molecular targeting dru
细胞通透肽抑制胰腺导管腺癌细胞增殖,可作为分子靶向药物
- 批准号:
25461969 - 财政年份:2013
- 资助金额:
$ 48.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic Research for elucidation of chemo-resistance in mucinous adenocarcinoma cell.
阐明粘液腺癌细胞化疗耐药性的基础研究。
- 批准号:
22791532 - 财政年份:2010
- 资助金额:
$ 48.87万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
TAS::75 0849::TAS IN THIS PHASE I SBIR THE BREAST CANCER ADENOCARCINOMA CELL LI
TAS::75 0849::TAS 在这一阶段 I SBIR 乳腺癌腺癌细胞 LI
- 批准号:
8164743 - 财政年份:2010
- 资助金额:
$ 48.87万 - 项目类别:
Role of Endothelin-1 in osteoblastic bone metastasis produced by a human lung adenocarcinoma cell line
Endothelin-1 在人肺腺癌细胞系产生的成骨细胞骨转移中的作用
- 批准号:
19790127 - 财政年份:2007
- 资助金额:
$ 48.87万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
CONNEXIN 43 EXPRESSION IN ADENOCARCINOMA CELL LINE
连接蛋白 43 在腺癌细胞系中的表达
- 批准号:
6972483 - 财政年份:2004
- 资助金额:
$ 48.87万 - 项目类别:
The mechanisms of highly metastetic capasity in highly metastatic subpopulations of lung adenocarcinoma cell line and these clinical applications
肺腺癌细胞系高转移亚群的高转移能力机制及临床应用
- 批准号:
15590831 - 财政年份:2003
- 资助金额:
$ 48.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)